Expressions of CD44 and IMP3 in epithelial ovarian cancer
印永祥,王曦辉,赵华,王家俊,陆牡丹,张婷,唐秋莎,陈道桢
DOI: https://doi.org/10.7620/zgfybj.j.issn.1001-4411.2017.10.59
2017-01-01
Abstract:Objective To explore the expressions of CD44 and IMP3 in epithelial ovarian cancer.Methods Fifty-nine patients with epithelial ovarian cancer treated in the hospital from May 2007 to February 2015 were selected as epithelial ovarian cancer group,18 patients with benign ovarian tumors were selected as control group during the same period.Immunohistochemistry was used to detect the expressions of CD44 and IMP3 in the two groups.The data was analyzed by SPSS 19.0 statistical software,inspection level was 0.05.Results The expression scores of CD44 in epithelial ovarian cancer group and control group were (3.78±2.55) points and (1.89±2.91) points,respectively,there was statistically significant difference between the two groups (Z=-2.817,P＜0.05).In epithelial ovarian cancer group,there was no statistically significant difference in the expression score of CD44 between the patients less than 50 years old and the patients aged 50 years old or more than 50 years old (Z=-1.213,P＞0.05);there was no statistically significant difference in the expression score of CD44 between the patients of stage Ⅲ-Ⅳ and the patients of stage Ⅰ-Ⅱ (Z =-1.947,P＞0.05);there was statistically significant difference in the expression score of CD44 between the patients with peritoneal metastasis and the patients without peritoneal metastasis (Z=-2.169,P＜0.05).The expression scores of IMP3 in epithelial ovarian cancer group and control group were (5.45 ±2.75) points and (1.67±1.41) points,respectively,there was statistically significant difference between the two groups (Z=-1.970,P＜0.05).In epithelial ovarian cancer group,there was no statistically significant difference in the expression score of IMP3 between the patients less than 50 years old and the patients aged 50 years old or more than 50 years old (Z=-1.201,P＞0.05);there was no statistically significant difference in the expression score of IMP3 between the patients of stage Ⅲ-Ⅳ and the patients of stage Ⅰ-Ⅱ (Z=-0.622,P＞0.05);there was no statistically significant difference in the expression score of IMP3 between the patients with peritoneal metastasis and the patients without peritoneal metastasis (Z=-1.169,P＞0.05).In epithelial ovarian cancer group,there was no correlation between CD44 expression and IMP3 expression (r =0.188,P＞0.05).Conclusion IMP3 may play a synergistic role in oncogenesis and aggravation of epithelial ovarian cancer,CD44 is important in peritoneal metastasis,which can be used as a new therapeutic target for epithelial ovarian cancer.